Suppr超能文献

育亨宾与吡啶斯的明治疗自主神经衰竭性直立性低血压的疗效比较。

Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure.

机构信息

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn, USA.

出版信息

Hypertension. 2010 Nov;56(5):847-51. doi: 10.1161/HYPERTENSIONAHA.110.154898. Epub 2010 Sep 13.

Abstract

Orthostatic hypotension affects patients with autonomic failure producing considerable disability because of presyncopal symptoms. Severely affected patients may have residual sympathetic tone that can be engaged to increase blood pressure (BP) with the α-2 adrenergic antagonist yohimbine. This medication activates sympathetic outflow centrally and unrestrains norepinephrine release from noradrenergic neurons. Alternatively, the acetylcholinesterase inhibitor, pyridostigmine, can increase sympathetic tone by improving ganglionic cholinergic neurotransmission. Our purpose was to compare these complementary approaches and to explore whether the combination would lead to synergistic increases in BP. We compared the effects of 60 mg of pyridostigmine and 5.4 mg of yohimbine in a single-blind, randomized, placebo-controlled, crossover fashion. In a subset of patients we tested the combination of pyridostigmine and yohimbine. Our primary outcome was the change in standing diastolic BP 60 minutes after drug administration from baseline. We studied a total of 31 patients with severe autonomic failure. Yohimbine significantly improved standing diastolic BP as compared with placebo (11±3 mm Hg [95% CI: 6 to 16 mm Hg]; P<0.001). On the contrary, pyridostigmine did not increase the standing diastolic BP (0.6±3 mm Hg [95% CI: -5 to 5 mm Hg]; P=0.823). Only yohimbine showed a significant improvement in presyncopal symptoms. Sixteen patients received the combination of pyridostigmine and yohimbine, but no evidence of synergistic pressor effect was found. Engaging residual sympathetic tone with yohimbine is a more effective approach to improve orthostatic hypotension as compared with pyridostigmine in patients with severe orthostatic hypotension.

摘要

直立性低血压影响自主衰竭患者,导致预晕厥症状出现相当大的残疾。严重受影响的患者可能残留有交感神经张力,可以用α-2 肾上腺素能拮抗剂育亨宾来增加血压 (BP)。这种药物在中枢激活交感传出,并抑制去甲肾上腺素从去甲肾上腺素能神经元释放。或者,乙酰胆碱酯酶抑制剂吡啶斯的明可以通过改善神经节胆碱能神经传递来增加交感神经张力。我们的目的是比较这些互补的方法,并探讨组合是否会导致血压协同增加。我们比较了 60 毫克吡啶斯的明和 5.4 毫克育亨宾在单盲、随机、安慰剂对照、交叉方式下的效果。在一组患者中,我们测试了吡啶斯的明和育亨宾的组合。我们的主要结果是药物治疗后 60 分钟站立舒张压与基线相比的变化。我们共研究了 31 名严重自主衰竭患者。与安慰剂相比,育亨宾显著改善站立舒张压 (11±3 毫米汞柱 [95%CI:6 至 16 毫米汞柱];P<0.001)。相反,吡啶斯的明并没有增加站立舒张压 (0.6±3 毫米汞柱 [95%CI:-5 至 5 毫米汞柱];P=0.823)。只有育亨宾改善了预晕厥症状。16 名患者接受了吡啶斯的明和育亨宾的联合治疗,但没有发现协同升压作用的证据。与吡啶斯的明相比,用育亨宾激发残留的交感神经张力是改善严重直立性低血压患者直立性低血压的更有效方法。

相似文献

1
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure.
Hypertension. 2010 Nov;56(5):847-51. doi: 10.1161/HYPERTENSIONAHA.110.154898. Epub 2010 Sep 13.
2
Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension.
Hypertension. 2019 Jan;73(1):235-241. doi: 10.1161/HYPERTENSIONAHA.118.11790.
4
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Hypertension. 2014 Dec;64(6):1235-40. doi: 10.1161/HYPERTENSIONAHA.114.04225. Epub 2014 Sep 2.
5
Acetylcholinesterase inhibition in patients with orthostatic intolerance.
J Clin Neurophysiol. 2006 Oct;23(5):476-81. doi: 10.1097/01.wnp.0000229946.01494.4c.
6
Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.
Hypertension. 2012 Mar;59(3):650-6. doi: 10.1161/HYPERTENSIONAHA.111.184812. Epub 2012 Feb 6.
7
Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
Arch Neurol. 2006 Apr;63(4):513-8. doi: 10.1001/archneur.63.4.noc50340. Epub 2006 Feb 13.
8
Effects of yohimbine, an alpha 2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension.
Fundam Clin Pharmacol. 1997;11(6):567-75. doi: 10.1111/j.1472-8206.1997.tb00862.x.
9
Pyridostigmine in the treatment of orthostatic intolerance.
Ann Pharmacother. 2007 Feb;41(2):314-8. doi: 10.1345/aph.1H458. Epub 2007 Feb 6.
10
Contrasting actions of pressor agents in severe autonomic failure.
Am J Med. 1998 Aug;105(2):116-24. doi: 10.1016/s0002-9343(98)00193-4.

引用本文的文献

2
Pyridostigmine in the management of orthostatic hypotension: a systematic review and meta-analysis.
Open Heart. 2025 Mar 25;12(1):e003106. doi: 10.1136/openhrt-2024-003106.
3
Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension.
Hypertension. 2025 Mar;82(3):489-497. doi: 10.1161/HYPERTENSIONAHA.124.24050. Epub 2024 Dec 27.
4
Adrenoceptors and Hypertension.
Handb Exp Pharmacol. 2024;285:297-332. doi: 10.1007/164_2024_719.
5
Benefits and Risks of Medications Used in the Management of Hypotension: A Review.
Cureus. 2024 Jan 3;16(1):e51608. doi: 10.7759/cureus.51608. eCollection 2024 Jan.
6
Orthostatic Hypotension in Adults With Hypertension: A Scientific Statement From the American Heart Association.
Hypertension. 2024 Mar;81(3):e16-e30. doi: 10.1161/HYP.0000000000000236. Epub 2024 Jan 11.
7
Parkinson's disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment.
Ann Med Surg (Lond). 2023 Aug 8;85(10):4887-4902. doi: 10.1097/MS9.0000000000001142. eCollection 2023 Oct.
8
Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments.
Handb Exp Pharmacol. 2024;285:507-554. doi: 10.1007/164_2023_675.
9
Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions.
J Neurol. 2023 Nov;270(11):5251-5273. doi: 10.1007/s00415-023-11876-y. Epub 2023 Jul 21.
10
Diagnosis and treatment of orthostatic hypotension.
Lancet Neurol. 2022 Aug;21(8):735-746. doi: 10.1016/S1474-4422(22)00169-7.

本文引用的文献

1
Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes.
Clin Neuropharmacol. 2006 May-Jun;29(3):97-105. doi: 10.1097/01.WNF.0000220822.80640.0D.
2
Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
Arch Neurol. 2006 Apr;63(4):513-8. doi: 10.1001/archneur.63.4.noc50340. Epub 2006 Feb 13.
3
Management of hypertension in the setting of autonomic failure: a pathophysiological approach.
Hypertension. 2005 Apr;45(4):469-76. doi: 10.1161/01.HYP.0000158835.94916.0c. Epub 2005 Feb 28.
4
Treatment of orthostatic hypotension.
Semin Neurol. 2003 Dec;23(4):435-42. doi: 10.1055/s-2004-817727.
5
Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension.
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1294-8. doi: 10.1136/jnnp.74.9.1294.
6
Hypertensive cardiovascular damage in patients with primary autonomic failure.
Lancet. 2000 Feb 26;355(9205):725-6. doi: 10.1016/S0140-6736(99)05320-9.
7
Contrasting actions of pressor agents in severe autonomic failure.
Am J Med. 1998 Aug;105(2):116-24. doi: 10.1016/s0002-9343(98)00193-4.
8
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Neurology. 1998 Jul;51(1):120-4. doi: 10.1212/wnl.51.1.120.
9
N(N)-nicotinic blockade as an acute human model of autonomic failure.
Hypertension. 1998 May;31(5):1178-84. doi: 10.1161/01.hyp.31.5.1178.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验